drugset / Trial / NCT02461745
Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic hepatitis C subjects aged 18 years and older, with VIEKIRA PAK (ombitasvir, paritaprevir/r, dasabuvir), with or without RBV (ribavirin).
Timeline
- Start
- 2015-06
- Primary completion
- 2017-05
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ribavirin | Small molecule | — | — |
| Comparator | Ritonavir | Other / unclassified | 50 mg | — |
| Comparator | dasabuvir | Small molecule | 250 mg | — |
| Comparator | ombitasvir | Small molecule | 12.5 mg | — |
| Comparator | paritaprevir | Small molecule | 75 mg | — |